Virtus LifeSci Biotech Products ETF

BBP
ETF Ticker

+30.83%

+43.58%

NYSE Arca Exchange

Equity

United States

Sector

The Virtus LifeSci Biotech Products ETF, BBP_US, is listed on the NYSE Arca Exchange and tracks the LifeSci Biotechnology Products index. The fund provides exposure to United States, Sector Equity and has assets under management of $116.0m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Dec 17, 2014. It has a net expense ratio of 79bps. (All data in USD as of Oct 15, 2026 unless stated.)

The underlying LifeSci Biotechnology Products Index provides equal-weighted exposure to U.S. exchange-listed biotechnology companies that already have at least one U.S. Food and Drug Administration-approved drug therapy marketed as a primary product. The universe is drawn from common shares and ADRs classified as biotechnology on U.S. exchanges; constituents must meet the index provider’s minimum market-cap, free-float and liquidity screens to support index capacity and tradability. From this investable universe, only issuers whose approved product or lead therapy represents a central part of the business model are included, emphasizing firms in the commercial “product” stage rather than development-only companies. All eligible names are included and assigned equal weights at each review, so smaller mid-cap and select small-cap issuers can carry similar index influence as larger peers. The index is typically reconstituted and rebalanced semi-annually, with deletions and additions implemented at those reviews.

ETF Details

Key Facts

Issuer:
Virtus
AUM:
$116.0m (as of Aug 31, 2026)
Net Expense Ratio:
79 bps
Inception Date:
Dec 17, 2014
Index:
LifeSci Biotechnology Products Index
Dividend Frequency:
Annually

Trading

Ticker:
BBP
Exchange:
NYSE Arca Exchange
ISIN:
US26923G2021
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
United States
Theme:
Sector
Economic Development:
Developed Markets
1 Year Volatility:
26.13%
3 Year Volatility:
24.83%
5 Year Volatility:
26.74%

Performance

TTM Dividend Yield:
0.00% (verify with issuer)
1 Month Performance:
3.38%
3 Month Performance:
6.48%
6 Month Performance:
19.73%
1 Year Performance:
43.58%
3 Year Performance:
115.58%
5 Year Performance:
106.79%
Investment Proposition

Virtus LifeSci Biotech Products ETF (BBP) presents exposure to biotechnology companies with commercialized therapies, emphasizing product revenue, market adoption and life-cycle durability rather than pre-revenue optionality. The strategy targets firms where cash-flow visibility and portfolio breadth can moderate binary trial risk relative to pure clinical-stage baskets, while remaining sensitive to pricing dynamics, competitive launches, label expansions and reimbursement decisions. Style characteristics often skew toward quality-growth within health care, with idiosyncratic drivers tied to product mix and pipeline productivity. The fund may benefit when health-care defensiveness is in demand, when innovation drives category expansion, or when rate volatility challenges more speculative growth; it can lag during early-cycle, high-beta rallies or when policy uncertainty around drug economics intensifies. Use cases include a healthcare-innovation core/satellite, a complement to broad health-care to deepen exposure to commercial biopharma, and factor completion for quality-growth. Suitable profiles include sector allocators seeking revenue-anchored biotech and diversified investors aiming to balance clinical-stage risk elsewhere. A key risk to monitor is concentration in a limited number of flagship products, where competitive pressures or payer actions can disproportionately influence results.

ETF Analytics

Fund Discovery

4 Suggestions